Japan · Advertising framework
Podcast advertising and host-read promotions for prescription medicines in Japan
General market orientation, not campaign clearance. Research scope and dates
Product and service rules
Medical-use medicine advertising is restricted to professionals
Regulator guidance
The 2017 advertising standards restrict public promotion of medicines supplied for use by physicians or dentists, or under their prescription or direction. Do not treat a public social account as a professional channel.
Sources: Standards for Fair Advertising of Pharmaceuticals and related products, 2017
Check the professional-recommendation restriction
Regulator guidance
The advertising standards restrict specified professional and institutional recommendations. Check the exact endorser and product before commissioning an expert testimonial.
Sources: Standards for Fair Advertising of Pharmaceuticals and related products, 2017
Check approval before promoting a product’s name or performance
Legal requirement — paraphrased
Applies when: The product falls within the approval/certification categories specified by Article 68.
MHLW’s PMD Act summary identifies Article 68 as a prohibition on advertising the name, manufacture, efficacy, effect or performance of specified medicines and devices before required approval or certification. Describing an offer as pre-launch does not itself establish an exemption.
Determine the Japanese regulatory route for the exact product or software function before publishing a campaign. This module does not classify every health app as a medical device.
Sources: MHLW: advertising regulation under the PMD Act · PMD Act Article 68 as reproduced by MHLW
Channel rules
Check the complete consumer-facing message
Regulator guidance
The misleading-representations regime covers goods and services, including misleading impressions about quality or price advantages. Review the full presentation and offer conditions. A truthful individual detail does not justify a deceptive overall claim.
Sources: Establishing Trusted Representation
Advertiser-directed content must be recognisable as advertising
Regulator guidance
CAA’s stealth-marketing rule addresses a supplying advertiser involved in determining a representation whose commercial nature consumers cannot recognise. Assess the brand’s role in the content and the overall presentation, including commissioned posts and reviews.
An influencer acting only as the commissioned publisher is generally not the regulated advertiser under this particular designation; CAA identifies joint supply of the product as an exception. This does not exempt the content from product-advertising law or other duties.
Sources: Stealth marketing regulation from 1 October 2023; CAA — Stealth marketing questions and answers · CAA stealth-marketing FAQ Q1
Review the spoken promotion
Editorial recommendation
Assess the host-read wording and audible identification within the recording. Do not assume listeners will open show notes. Decide whether a filmed or broadcast version needs a separate review.
Campaign workflow
Prescription Medicines: prepare the review
Editorial recommendation
Identify the exact authorised medicine and prescription status. Resolve the public-promotion restriction or permitted route before developing creative. Separate medicine promotion from neutral disease information and healthcare-service advertising.
Keep a traceable campaign decision
Editorial recommendation
Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.
Pre-publication checklist
- Identify the exact authorised medicine and prescription status.
- Resolve the public-promotion restriction or permitted route before developing creative.
- Separate medicine promotion from neutral disease information and healthcare-service advertising.
- Record product or provider eligibility before approving claims.
- Archive the final creative and its evidence, permissions and review decisions.
- Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.
Scope and unresolved questions
- March 2026 sixth-edition medical advertising examples, website exemption conditions and FFC transitions have been checked. Remaining checks concern prefectural implementation, practitioner-specific and pharmacy requirements, actual product notifications and treatment disclosures, personal-information processing and each messaging technology. This pack does not supply every Japanese mandatory warning text.
- This national baseline does not review every broadcaster rule, platform policy, regional licensing condition, promotion mechanic or data-transfer arrangement. No format-specific warning dimensions or durations should be inferred where none are supplied.
Research scope, introduction and dates
Prescription-medicine advertising in podcasts and digital audio in Japan starts with a legal eligibility decision. Establish whether the proposed consumer message is permitted, restricted to limited information or confined to a professional route before developing benefit and risk statements.
Podcast listeners may hear a promotion without seeing its show notes. Assess audible commercial identification, the host's statements and required spoken information in the recording itself; a filmed podcast also needs a visual-format review.
General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.
How to use this national baseline
Editorial overview
This framework combines researched national rules with editorial review steps. Japanese product and medical-service advertising baseline; local and product-specific implementation requires review. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.
The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.
Sources
- Standards for Fair Advertising of Pharmaceuticals and related products, 2017
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Establishing Trusted Representation
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Stealth marketing regulation from 1 October 2023
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- CAA — Stealth marketing questions and answers
Targeted review on 25 October 2026. This date does not certify the currency of other sources or resolve local and campaign-specific requirements.
- MHLW: advertising regulation under the PMD Act
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
From framework to action
Local expertise in Japan
Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in Japan.
Medical & health marketing
No partners listed in this category yet.
Marketing & sales advisory
No partners listed in this category yet.
Business & project coordination
No partners listed in this category yet.
Join the local partner directory
Would you like your company to be listed?
Talk to us about the terms of a listing. Leave your details and we will get in touch.